| Old Articles: <Older 6721-6730 Newer> |
|---|
 |
The Motley Fool
September 27, 2010
Seth Jayson |
How Is MedcoHealth's Performance at the Margin? Here's the current margin snapshot for MedcoHealth and some of its sector and industry peers and direct competitors.   |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
The Motley Fool
September 24, 2010
Brian Orelli |
Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front. |
The Motley Fool
September 24, 2010
Brian Orelli |
So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership. |
The Motley Fool
September 24, 2010
Seth Jayson |
How's SonoSite's Performance at the Margin? Here's the current margin snapshot for SonoSite and some of its sector and industry peers and direct competitors. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
September 23, 2010
Brian Orelli |
A Blockbuster in Due Time Novartis' new multiple sclerosis drug, Gilenya, isn't king yet. |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
| <Older 6721-6730 Newer> Return to current articles. |
